Production (Stage)
ARYx Therapeutics, Inc.
ARYX
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | 0.00 |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 8.17M | 9.49M | 9.97M | 10.20M | 9.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.23M | 20.71M | 26.47M | 31.24M | 38.45M |
| Operating Income | -15.23M | -20.71M | -26.47M | -31.24M | -38.45M |
| Income Before Tax | -18.33M | -23.96M | -29.72M | -33.17M | -40.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.33 | -23.96 | -29.72 | -33.17 | -40.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.33M | -23.96M | -29.72M | -33.17M | -40.43M |
| EBIT | -15.23M | -20.71M | -26.47M | -31.24M | -38.45M |
| EBITDA | -14.28M | -19.79M | -25.43M | -30.16M | -37.36M |
| EPS Basic | -0.61 | -0.83 | -1.07 | -1.21 | -1.57 |
| Normalized Basic EPS | -0.35 | -0.49 | -0.64 | -0.76 | -0.98 |
| EPS Diluted | -0.61 | -0.83 | -1.07 | -1.21 | -1.57 |
| Normalized Diluted EPS | -0.35 | -0.49 | -0.64 | -0.76 | -0.98 |
| Average Basic Shares Outstanding | 123.86M | 117.84M | 111.76M | 109.75M | 105.08M |
| Average Diluted Shares Outstanding | 123.86M | 117.84M | 111.76M | 109.75M | 105.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |